Related Experiment Videos
Centralized drug review processes: are they fair?
Craig R Mitton1, Meghan McMahon, Steve Morgan
1Faculty of Health and Social Development, University of British Columbia Okanagan, 3333 University Way, Kelowna, British Columbia, Canada V1V1V7. craig.mitton@ubc.ca
Social Science & Medicine (1982)
|January 24, 2006
Summary
Centralized drug review processes worldwide need improvement in fairness. A study found that while these systems meet some ethical conditions, none fully satisfy all four, highlighting transparency as crucial for legitimacy.
Area of Science:
- Health Policy
- Medical Ethics
- Pharmaceutical Policy
Background:
- Centralized drug review processes are common globally for drug coverage decisions.
- Ensuring fairness in these priority-setting processes is essential.
- Accountability for Reasonableness (AFR) is an ethical framework for assessing fairness.
Purpose of the Study:
- To assess the fairness of four international centralized drug review processes.
- To evaluate these processes using the Accountability for Reasonableness framework.
Main Methods:
- Conducted semi-structured telephone interviews with 16 stakeholders.
- Included participants from Canada, New Zealand, Australia, and the UK.
- Stakeholders evaluated their country's process against the four conditions of AFR.
Main Results:
- Each reviewed process met at least one of the four AFR conditions.
- No centralized drug review process met all four AFR conditions.
- Transparency was universally identified as critical for legitimacy and fairness.
Conclusions:
- Further improvements are needed in the fairness of centralized drug review processes in the studied countries.
- Fair priority setting should promote stakeholder engagement and decision legitimacy.
- Fairness in resource allocation for pharmaceuticals is increasingly important for policymakers.